UNITED STATES – A new generic treatment option for people with type 2 diabetes has been approved by the FDA.
The generic version is a daily injectable GLP-1 medicine, originally sold under the brand name Victoza.
While the company behind the generic has not disclosed a specific price, it stated that the cost will be less than the branded version. The branded drug can cost up to $815 per package before discounts or insurance.
The FDA noted that there has been a shortage of the name brand drug in the U.S. since July 2023.
